Current Medical Research and Opinion

Vol. 12, No. 5, 1991

Intranasal budesonide once daily in seasonal allergic rhinitis

M. Bhatia,M.B.,B.S.,M.R.C.G.P., L. M. Campbell,* M.B., Ch.B., M.R.C.G.P.,

Curr Med Res Opin Downloaded from informahealthcare.com by Nyu Medical Center on 02/09/15 For personal use only.

J.R. M. Ross,**M.R.C.S., L.R.C.P., M. D. Taylor,*** Ph.D., E. M. Peers,*** Ph.D., and P. D. I. Richardson,*** Ph.D. General Practice, Leeds, *Glasgow, and **Huddersfield, and ***MedicalDepartment, Astra Pharmaceuticals Ltd., Kings Langley, England

Curr. Med. Res. Opin., (1991), 12,287.

Received: 22nd October 1990

Summary A double-blind, parallel-group, multi-centre study was carried out in 248patients with symptomatic seasonal allergic rhinitis to assess the effectiveness and tolerability of intranasal aqueous budesonide given as a single daily dose each morning of 400 pg compared with the conventional dosage regimen of 200 pg twice daily. After a 1-week run-in period during which only oral terfenadine was allowed f o r intolerable symptom relieJ symptomatic patients were allocated at random to receive budesonide in one or other dosage regimen for 3 weeks. The results of assessments made by the phisician at clinic visits and by patients recording daily data on diary record cards showed that specific nasal symptom incidence and severity were significantly (p